(19)
(11) EP 4 284 798 A1

(12)

(43) Date of publication:
06.12.2023 Bulletin 2023/49

(21) Application number: 22705222.2

(22) Date of filing: 26.01.2022
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 35/00(2006.01)
A61K 31/4985(2006.01)
C07D 487/04(2006.01)
A61K 31/437(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 471/04; C07D 487/04; A61P 35/00
(86) International application number:
PCT/US2022/013946
(87) International publication number:
WO 2022/164934 (04.08.2022 Gazette 2022/31)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 26.01.2021 US 202163141634 P

(71) Applicant: The USA, as represented by The Secretary, Department of Health and Human Services
Bethesda, MD 20892-7660 (US)

(72) Inventors:
  • ZHAO, Xuezhi
    Bethesda, MD 20892-7660 (US)
  • WANG, Wenjie
    Bethesda, MD 20892-7660 (US)
  • LOUNTOS, George, Themistoclis
    Frederick, MD 21702-1201 (US)
  • KISELEV, Evgeny, Anatolyevich
    Bethesda, MD 20892-7660 (US)
  • WAUGH, David, Spencer
    Bethesda, MD 20892-7660 (US)
  • POMMIER, Yves, Georges
    Bethesda, MD 20892-7660 (US)
  • BURKE, Terrence, Richard, Jr.
    Bethesda, MD 20892-7660 (US)

(74) Representative: Harris, Oliver John Richard 
Novagraaf UK Centrum Norwich Research Park Colney Lane
Norwich NR4 7UG
Norwich NR4 7UG (GB)

   


(54) IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS